RIGL News and Press, Rigel Pharmaceuticals Inc. From 02/24/26

Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will repor...

2026-02-10 14:51:07 ET More on small caps Sally Beauty Holdings: Things Are Slowly Improving With This House Position Sally Beauty Holdings Is Stunning Sally Beauty Holdings, Inc. (SBH) Q1 2026 Earnings Call Transcript Nektar eyes late-stage program for eczem...

Rigel Appoints Michael P. Miller to the Board of Directors PR Newswire SOUTH SAN FRANCISCO, Calif. , Feb. 3, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has appointed Michael P. Miller to its Board of Directors. Mr. Miller...

2026-01-26 22:40:08 ET ... Read the full article on Seeking Alpha For further details see: Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026

2026-01-15 03:25:59 ET Rigel Pharmaceuticals, Inc. (RIGL) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 6:00 PM EST... Read the full article on Seeking Alpha For further details see: Rigel Pharmaceuticals, Inc. (RIGL) Presents at 44th Annual J.P. Morgan Heal...

Rigel Provides Business Update and 2026 Outlook PR Newswire Preliminary fourth quarter 2025 total revenue of approximately $69.8 million , including net product sales of $65.4 million and contract revenues of $4.4 million In the dose escalation phase of the Phase 1b stud...

Rigel to Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire SOUTH SAN FRANCISCO, Calif. , Jan. 7, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, ...

2026-01-01 04:41:46 ET It has been seven years since my first Rigel Pharmaceuticals ( RIGL ) article, where I was bullish on TAVALISSE and the company's impressive pipeline. I was eyeing a potential buy early in 2019 as the company continued to make headway clinically and commer...

2025-12-22 08:30:48 ET Now that 2025 is nearing its close and the holidays are upon us, I want to wish readers a joyous year-end holiday season. You likely have festivities to attend (and I do too), but as the year winds down I wanted to close with my annual performance review. Busi...

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition PR Newswire R289 continues to be generally well tolerated and at doses of ≥500 mg QD preliminary efficacy was observed i...